{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=109",
    "query": {
      "condition": "Advanced Solid Neoplasm",
      "page": 109
    },
    "page_size": 10
  },
  "pagination": {
    "page": 109,
    "page_size": 10,
    "total_count": 3389,
    "total_pages": 339,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=110&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=108&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T19:53:39.298Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06760819",
      "title": "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "HER2 Mutation"
      ],
      "interventions": [
        {
          "name": "BAY2927088",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2025-02-13",
      "completion_date": "2029-10-26",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-16T19:53:39.298Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06760819"
    },
    {
      "nct_id": "NCT03735628",
      "title": "An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)",
        "Head and Neck Squamous Cell Carcinoma (HNSCC)",
        "Hepatocellular Carcinoma (HCC)"
      ],
      "interventions": [
        {
          "name": "Copanlisib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2018-10-17",
      "completion_date": "2022-10-13",
      "has_results": false,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-11-16T19:53:39.298Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Denver, Colorado + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03735628"
    },
    {
      "nct_id": "NCT06823167",
      "title": "A Phase 1 Study of IM-1021 in Participants With Advanced Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Malignancies",
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "IM-1021",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunome, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2025-02-26",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-11-16T19:53:39.298Z",
      "location_count": 19,
      "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 16 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06823167"
    },
    {
      "nct_id": "NCT06162221",
      "title": "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer, NSCLC",
        "KRAS, NRAS, HRAS-mutated NSCLC",
        "KRAS G12C-mutated Solid Tumors, Lung Cancer",
        "Lung Cancer Stage IV, Advanced Solid Tumor, Cancer",
        "RAS G12D-mutated NSCLC"
      ],
      "interventions": [
        {
          "name": "RMC-6291",
          "type": "DRUG"
        },
        {
          "name": "RMC-6236",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "RMC-9805",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 616,
      "start_date": "2024-01-18",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-16T19:53:39.298Z",
      "location_count": 29,
      "location_summary": "Gilbert, Arizona • Duarte, California • Irvine, California + 24 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06162221"
    },
    {
      "nct_id": "NCT06777316",
      "title": "A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Intrahepatic Cholangiocarcinoma (Icc)",
        "Cholangiocarcinoma",
        "Other Solid Tumors, Adult",
        "FGFR2 Gene Fusion/Rearrangement",
        "FGFR2 Gene Amplification",
        "FGFR2 Gene Short Variants",
        "FGFR3 Gene Fusion/Rearrangement",
        "FGFR3 Gene Amplification",
        "FGFR3 Gene Short Variants",
        "FGFR2 Genetic Alterations",
        "FGFR3 Genetic Alterations",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "CGT4859",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cogent Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2025-01-22",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-11-16T19:53:39.298Z",
      "location_count": 12,
      "location_summary": "Palo Alto, California • Jacksonville, Florida • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06777316"
    },
    {
      "nct_id": "NCT07213830",
      "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor"
      ],
      "interventions": [
        {
          "name": "IPN01203",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2026-02-06",
      "completion_date": "2032-07-14",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-11-16T19:53:39.298Z",
      "location_count": 4,
      "location_summary": "Grand Rapids, Michigan • Nashville, Tennessee • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07213830"
    },
    {
      "nct_id": "NCT05094336",
      "title": "A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced MTAP-null Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Anvumetostat",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Comparator Anvumetostat Test Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 329,
      "start_date": "2022-02-01",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-11-16T19:53:39.298Z",
      "location_count": 30,
      "location_summary": "Duarte, California • Glendale, California • Oxnard, California + 24 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Margate",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05094336"
    },
    {
      "nct_id": "NCT00028821",
      "title": "2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Multiple Myeloma",
        "Stage III Multiple Myeloma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "2-methoxyestradiol",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2002-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-11-16T19:53:39.298Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00028821"
    },
    {
      "nct_id": "NCT03514121",
      "title": "FPA150 in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "FPA150",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Five Prime Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 95,
      "start_date": "2018-03-27",
      "completion_date": "2021-04-21",
      "has_results": true,
      "last_update_posted_date": "2024-11-22",
      "last_synced_at": "2026-11-16T19:53:39.298Z",
      "location_count": 13,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03514121"
    },
    {
      "nct_id": "NCT06694480",
      "title": "Study of FID-022 in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "FID-022",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fulgent Pharma LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2025-07-03",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-11-16T19:53:39.298Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Los Angeles, California • Tampa, Florida",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06694480"
    }
  ]
}